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Platelets contribute to processes beyond thrombus formation and may play a so far under-
estimated role as an immune cell in various circumstances. This review outlines immune
functions of platelets in host defense, but also how they may contribute to mechanisms
of infectious diseases. A particular emphasis is placed on the interaction of platelets with
other immune cells. Furthermore, this article outlines the features of atherosclerosis as
an inflammatory vascular disease highlighting the role of platelet crosstalk with cellular
and soluble factors involved in atheroprogression. Understanding, how platelets influence
these processes of vascular remodeling will shed light on their role for tissue homeosta-
sis beyond intravascular thrombosis. Finally, translational implications of platelet-mediated
inflammation in atherosclerosis are discussed.
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INTRODUCTION
The vasculature is one of the large networks of the human body
and, thus, it needs to be well protected by immune mechanisms.
When tissue is injured, the wound is paralleled by a severance of
the vascular network, as well. Disruption of the endothelial mono-
layer lining all vessels from the inside triggers a process referred
to as thrombus formation, a well regulated and complex cascade
of events (1). During thrombus formation, other systems located
within the vasculature can be activated, the most prominent of
which is the immune system and inflammation being a part of
its innate response. The inflammatory response to tissue injury
triggers various events, which allow for defense against possible
intruders and initiate the healing process (2). Simultaneously and
in close proximity, platelets are recruited to the wound to restore
endothelial integrity; they are activated and initiate thrombus
formation. Given the close spatiotemporal relationship of these
molecular processes, it is not surprising that growing evidence
suggests that platelets are not only effectors of thrombus forma-
tion, but actively participate in inflammation and other processes
related to tissue remodeling (3).
PLATELETS PRESERVE VASCULAR INTEGRITY
Repair of vascular damage while simultaneously preserving the
patency of narrow capillaries is a complex task and requires a finely
tuned machinery of pro- as well as anti-thrombotic mechanisms.
Platelets are the key cells of primary hemostasis and thrombus for-
mation. They mediate thrombus formation through cellular and
soluble factors [recently also reviewed in Ref. (1, 4–7)]. GPIbα is a
platelet transmembrane receptor associated with GPIX and GPV
(8). GPIbα binding to von-Willebrand-factor (vWF) initiates pri-
mary hemostasis (8). In a shear-dependent fashion, GPIbαbinding
to vWF immobilized on collagen enables initial platelet rolling,
which precedes all further steps of thrombus formation (9). Except
at sites of high shear rates (10), stable platelet adhesion requires
additional contribution of GPVI and integrins (11). GPVI is one of
the platelet collagen receptors. It provides strong mechanic adhe-
sion but also serves as the primary inducer of platelet activation
mediated by its FcRγ-chain (12, 13). Amongst other signaling
events, activation of GPVI causes an elevation of intracellular
Ca2+ and subsequent platelet shape change (14). Platelet activa-
tion is paralleled by the secretion of soluble factors from platelet
granules, the most important of which are ADP and TxA2 (15–
17), as they activate platelets in an autocrine fashion (18). C-type
lectin-like type II (CLEC-2) supports GPVI as it sustains a similar
signaling pathway as the one induced by the GPVI/FcRγ complex
(19, 20). In fact, CLEC-2 was found to be of particular impor-
tance for stable aggregate formation under flow conditions (21).
The thrombotic activity of platelets is regulated by controlling the
surface density of these major receptors by ectodomain shedding
(22). A central process in platelet-mediated thrombus formation is
integrin activation, as integrins connect the ECM to the platelets’
cytoskeleton and enable platelet aggregate formation (11). The
integrinαIIbβ3 has the ability to“crosslink”platelets via fibrinogen-
bridging (23), thus stabilizing the forming thrombus. Due to its
central importance, its inside-out activation is referred to as the
“final common pathway of platelet activation” (24). The activa-
tion of αIIbβ3 is mediated by the classical platelet agonists ADP
or TxA2, and interfering with these pathways was successfully
transferred into patient treatment (25). Similar to other integrins,
αIIbβ3 promotes “outside-in” signaling as well as platelet spread-
ing and clot retraction (26). Finally, platelets also interact with
the coagulation system in various ways stabilizing the develop-
ing thrombus by fibrin formation, which provides for provisional
wound closure (27–29).
“NON-CLASSICAL” PLATELET FUNCTIONS
Although traditionally not conceived as immune cells, platelets
hold important functions in the immune response, particularly in
innate immunity (30–32). In both host defense and preservation
of vascular functions, platelets are helpful in some and harmful in
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other conditions (33). In the following, we will aim to exemplify
how platelets mediate effects beyond thrombus formation.
PLATELETS IN HOST DEFENSE
Platelets contribute to pathogen recognition by interacting with
immune cells, but also by interacting with the bacteria them-
selves (34–41). Recently, it was demonstrated that platelet-rich
plasma (PRP) inhibited the growth of bacteria (42). The various
receptor interactions involved in this platelet–bacteria crosstalk
were already reviewed elsewhere (43, 44). For instance, platelets
are able to recognize CpG islands upon thrombin activation and
subsequent TLR9 expression (40). Furthermore, platelets react
to fungal infections in vitro and in vivo (45). Finally, platelet
“nuclear functions”are increasingly uncovered and recognized (2).
Via transcription of mRNA and post-transcriptional modification
(46–48), platelets seem to contribute to the inflammasome by pro-
ducing IL-1β (49), they are involved in modulating NFκB (50) and
may influence endothelial polarization by miRNA secretion (51).
PLATELETS CONTRIBUTING TO MECHANISMS OF INFECTIONS
On the other hand, there are a number of reports describing
platelets as an important element in the progression of infections
(52). The platelet receptor CLEC-2 has been shown to facilitate the
entry of HI-viruses (53), and platelets contribute to disease pro-
gression via CD40L (54, 55). Furthermore, platelets are involved
in the progression of HBV-infection and other viral diseases (56,
57) by the recruitment of cytotoxic T-cells (CTL) to the liver (58)
or other organs in a serotonin-dependent manner (59). Verschoor
et al. could recently show that platelets are a relevant factor in the
process of immune evasion by intracellular bacteria such as Listeria
(38). Furthermore, platelets play an important role in infections
by Leishmania (60) and in the pathogenesis of Hantavirus infec-
tion (61). A fact, which complicates the picture even more, is that
platelets can also modulate the function of further cells involved
in the response to infections – the leukocyte.
PLATELET CROSSTALK WITH IMMUNE CELLS
One of the main immune mechanisms of platelets is their capa-
bility to recruit leukocytes to sites of infection and inflammation
(32, 62). P-selectin–PSGL-1 binding (63, 64), ICAM1 (51), and
GPIbα (65) play an important role in how platelets bring other
immune cells to the scene (66), particularly under high shear
conditions (67). Platelets have the ability to form aggregates with
neutrophils (68). In periodontitis, aggregate formation of platelets
and neutrophils (NPA) enhances neutrophil phagocytosis in a
TLR-2-dependent manner (69). In acute lung injury, NPA forma-
tion mediates neutrophil extravasation (70) and platelet-derived
platelet factor 4 (PF4) fostered neutrophil survival in a model
of arterial occlusion (71). Furthermore, platelet–leukocyte aggre-
gates can be used as a diagnostic tool, for example as a parameter
to assess sepsis severity (72). Another recently discovered way,
how platelets modulate neutrophil function is their involvement in
neutrophil extracellular trap (NET) formation to ensnare intrud-
ers (73). Platelet TLR-4 (74) as well as platelet β-defensins have
been implicated in NET formation (75, 76). Specifically, platelet-
induced NET formation may play a role in viral infections (77) or
transfusion-related lung injury (78). Rossaint et al. have recently
proposed that simultaneous activation of neutrophils via Mac-
1 outside-in signaling and Gαi engagement by platelet-derived
RANTES–PF4 heterodimers is required for NET formation (79).
Interestingly, platelets seem to form especially stable aggregates
with monocytes (80), and activated platelets induce an inflamma-
tory monocyte phenotype (81). As this process seems to be par-
tially independent of P-selectin interaction with PSGL-1,paracrine
mechanisms to strengthen platelet–monocyte aggregate formation
have been proposed as an alternative mechanism (81). Platelet–
monocyte interaction seems to be of functional relevance, as their
formation increases the number of circulating monocytes with
a higher affinity for adhesion to the endothelium (82). Further-
more, activated platelets are taken up by monocytes which induces
enhancement of cytokine release from macrophages (83). Other
authors, however, report on anti-inflammatory effects of platelet–
monocyte interaction (84–86) via CXCR5 engagement of CXCL13
on monocytes (84) or, following experimental sepsis, by inhibition
of macrophage tumor necrosis factor α (TNF-α) and IL-6 secre-
tion (85, 86). Thus, the effect of platelets on monocytes appears to
be context-dependent.
Via P-selectin PSGL-1 interaction, platelets can form aggre-
gates with lymphocytes (PLA), as well. Platelet interaction with
T-cells, B-cells, and NK-cells induces their homing, activation, and
recruitment as recently reviewed (87). Platelets may even serve as
a bridge directing T-cells to the endothelium (88). Furthermore,
platelets modulate lymphocyte function via direct cell–cell inter-
action as well as soluble mediators (87). In rheumatoid arthritis
patients, platelet binding to lymphocytes promoted activation-
induced proliferation as well as IL-17 and interferon-γ production
by GPVI positive CD4+ T-cells (89). Serotonin from platelet vesi-
cles may also stimulate T-lymphocytes (90). Through release of
PF4 and CCL5, platelets can enhance cytokine production in
CD4+ T-cells (34). Furthermore, in HCV infection, platelet CCL5
causes upregulation of T-lymphocyte helper cells type 1 (Th1)
(91). Finally, platelets may also enhance T-cell-mediated germi-
nal center formation and release of specific IgGs from B-cells
via CD40L signaling (35, 41). In fact, platelets may substitute
CD40L when few CD40L-positive T-cells are present to stimu-
late B-cell maturation (92). However, platelets may also induce
anti-inflammatory effects. PF4 released from platelets leads to
an increase in regulatory T-lymphocytes (Tregs) (93) and limits
Th17 differentiation (94). Interestingly, T-lymphocytes can acti-
vate platelets, which amplify the release of CCL5 (95). Addressing
antigen-presenting cells, there are a number of ways in which
platelets interact with dendritic cells (DCs). For instance, platelets
can recruit DC via Mac-1 interaction with JAM-C and can activate
them inducing platelet phagocytosis and subsequently apoptosis
of DCs (96). High shear rates may be a trigger for platelets to
recruit DCs and promote their maturation (97). In fact, direct
contact of platelets and DCs seems to induce other effects than
crosstalk via soluble factors suggesting that platelets have the abil-
ity to differentially regulate a DC response (98). This conclusion
is supported by recent findings demonstrating that platelets can
enhance DC-mediated Th-2 cell response in allergy by secreted
RANKL (99). Platelets can, however, also impair DC differen-
tiation or reduce DC production of proinflammatory cytokines
IL-12p70 and TNF-α (100).
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PLATELETS IN ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory disease featuring var-
ious complex processes contributing to its pathophysiology and
the development of the atherosclerotic plaque over decades.
Figure 1 summarizes the steps contributing to fatty streak forma-
tion, inflammation, progression of the plaque, and finally plaque
rupture.
PLATELET CONTRIBUTION TO ATHEROSCLEROSIS
In atherosclerosis, platelets are known to contribute to early steps
of this chronic vascular pathology (Figure 2) such as endothelial
dysfunction (101, 102), but also to final events such as rupture
of the vulnerable plaque [(103), see also Figure 4]. For instance,
platelets participate in atherogenesis by chemokine release (79,
104, 105), surface association of oxLDL (106), direct cell–cell
interaction (107, 108), release of microparticles (109), and pro-
vision of inflammatory mediators [(110), see also Figure 3].
Platelets within the atherosclerotic plaque may remain activated
for a long time providing for proinflammatory IL-1β production
[(111), see also Figure 3]. One of the most considered func-
tions of platelets in atherosclerosis is the recruitment of leukocytes
via direct receptor–ligand interactions or augmented by released
factors such as chemokines [(112, 113), see also previous sections
and Figure 3]. The role of a particular leukocyte subtype – DCs,
FIGURE 1 | Pathophysiology of atherosclerosis. During atherogenesis, a
plaque forms on the luminal side of the arterial wall through a complex
process involving lipid accumulation, cellular activation inducing the
transformation and differentiation of monocytes into foam cells, and various
immune reactions mediated by T- and B-cells, neutrophils, granulocytes
(neutrophils), and dendritic cells (DCs). Hence, the progression of
atherosclerosis is driven by inflammation, although some of these
inflammatory cells/factors may also mediate atheroprotection under certain
conditions. At later stages, the atherosclerotic plaque develops a necrotic
core with areas of neovascularization, a thin fibrous cap, and scattered
calcifications. Finally, plaque rupture exposes the thrombogenic
atherosclerotic core inducing platelet activation and, subsequently, initiation
of the coagulation cascade. Ab, antibody; Hb, hemoglobin; HSP, heat shock
protein; NET, neutrophil extracellular trap; PF4, platelet factor 4; SMC,
smooth muscle cell; Treg, regulatory T-cell; VALT, vascular-associated
lymphatic tissue.
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FIGURE 2 | Mechanisms, how platelets affect the initiation of
atherosclerosis. Upon activation within the microenvironment of the
atherosclerotic plaque or even at very early stages of atherogenesis in areas
of high shear stress, platelets express increased levels of inflammatory
adhesion receptors (ICAM1, intracellular adhesion molecule 1; GPIbα,
glycoprotein Ibα; αIIbβ3, glycoprotein αIIbβ3) associated with oxLDL binding to
platelets. TLR-mediated signaling may contribute via binding of
lipopolysaccharides (LPS), leukocyte interaction, or binding of
carboxyalkylpyrroles (CAPs). The complement system also contributes to
atherogenesis. MIF, macrophage migratory inhibitory factor; PF4, platelet
factor 4; RANTES, chemokine ligand 5 (CCL5); TLRs, Toll-like receptors;
oxLDL, oxidized low-density lipoprotein.
the classical antigen presenting cells of our body – has been empha-
sized recently in the context of atherosclerosis and, interestingly,
platelets interact with DCs (Figure 3). In fact, GPIb–Mac-1 inter-
action may be an interesting signaling mechanism in the context
of platelet–DC crosstalk modulating atheroprogression (114, 115).
This is of particular importance,as DCs have been proposed to play
a significant role in the different steps of atherosclerosis (116).
PLATELETS IN THE COMPLEMENT SYSTEM AND ATHEROSCLEROSIS
A further part of our innate immune response, the complement
system receives increasing attention in the context of atheroscle-
rosis. This cascade of soluble plasma proteins constitutes a phylo-
genetically very old part of the inherited immune system (117).
Complement activation is important for inflammatory condi-
tions associated with vascular injury (118, 119). Most interestingly,
platelets were reported to express a number of complement recep-
tors relevant for platelet function and their crosstalk with the local
microenvironment (120–122). Several complement components
can be bound to the platelet surface (123, 124). We found that
expression of complement anaphylatoxin receptors on platelets
showed a strong and positive correlation with platelet activa-
tion markers such as P-selectin in patients with atherosclerosis
(125). Further mechanistic studies will have to address the rel-
evance of this association. In a recent review, the literature on
platelets and potential intersection points with the complement
system in diverse settings was summarized (126). Additional pro-
found studies are needed to differentiate our understanding of
the intersection points of platelet activation with the immuno-
logical elements of atherogenesis such as endothelial inflamma-
tion, leukocyte recruitment, antigen presentation, chemokine and
cytokine production, or complement activation.
PLAQUE RUPTURE
At later stages, the atherosclerotic core becomes hypoxic inducing
the outgrowth of vasa vasorum from the adventitia toward the
intima [(127, 128), see also Figure 4]. As a consequence, fragile
and leaky vessels form, which facilitate further invasion of immune
cells and release of soluble factors into the surrounding atheroscle-
rotic tissue (129, 130). Moreover, red blood cells get stuck in the
plaque liberating hemoglobin and iron (131). These mechanisms
ultimately result in plaque destabilization (132). Foam cells pro-
duce tissue factor (133), and as soon as the thrombogenic lipid core
is exposed to the lumen, fibrin generation is initiated (134–136).
In parallel, platelets as well as the coagulation cascade become
activated (137, 138). Plaque rupture in the region of a thin fibrous
cap is the final event, how atherosclerosis causes acute vascular
complications such as myocardial infarction or stroke (139–143).
TRANSLATIONAL RELEVANCE
The fact that inflammation plays a key role in central steps of
atherosclerosis (31, 144), is increasingly integrated into clinical
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FIGURE 3 | Mechanisms, how platelets affect the progression of
atherosclerosis. Platelets contribute to the progression of atherosclerosis
by chemokine deposition (A) and leukocyte recruitment (B). Remnant
“nuclear” functions of platelets such as the ability to translate and modify
mRNA promote inflammation and endothelial polarization (C). Furthermore,
the interaction with antigen-presenting dendritic cells can contribute to
atheroprogression involving adhesion receptors and soluble mediators
(D). CXCR4, C-X-C chemokine receptor type 4 (CD184); SDF-1α, stromal
cell-derived factor 1α.
considerations. Accordingly, this hypothesis is addressed by
two current trials, the CANTOS trial launched in 2011 (145)
and the CIRT trial (146) using immunosuppressants to treat
FIGURE 4 | Mechanisms, how platelets affect plaque rupture. Plaque
rupture is tailored by platelets in several ways: platelets are known to
modulate angiogenesis, which is a decisive factor for plaque stability.
Platelets have also been found to promote smooth muscle cell (SMC)
progenitor recruitment via CXCR4-SDF-1α signaling. SMCs are responsible
for generating extracellular matrix stabilizing the fibrous cap of the plug.
Thrombus formation in areas of the ruptured fibrous cap exposing
components of the extracellular matrix is initiated by platelets. Future
investigations will also have to test, whether platelets enter the plaque
tissue and affect tissue remodeling. Ab, antibody; CD40L, CD40 ligand
(CD154); DC, dendritic cell; IL-1α, interleukin 1α; JAM-C, junctional adhesion
molecule type C; Mac-1, macrophage-1 antigen; MIF, macrophage
migratory inhibitory factor; miRNA, microRNA; NFκB, nuclear factor
kappa-light-chain-enhancer of activated B-cells; PF4, platelet factor 4;
PSGL-1, P-selectin glycoprotein ligand-1; RANKL, receptor activator of
nuclear factor kappa-B ligand; RANTES, chemokine ligand 5 (CCL5); TLRs,
Toll-like receptors; Treg, regulatory T-cell.
atherosclerosis. Earlier in this article, we have aimed at depict-
ing the importance of platelets for inflammation in atheroscle-
rosis. Inhibition of platelet-mediated inflammation may already
be everyday clinical practice considering the use of aspirin for
the treatment of cardiovascular disease (147). As an irreversible
inhibitor of the enzyme cyclooxygenase, aspirin is a mild inhibitor
of platelet function (148). Despite its widespread use, the def-
inite role of aspirin in the prevention of atherosclerosis and
atherosclerosis-related diseases is still under discussion (147).
There is evidence from preclinical studies that aspirin is able to
inhibit the initiation (149) and even the progression of experi-
mental atherosclerosis (150) via its effect on prostaglandin syn-
thesis but also by other mechanisms such as the modulation
of endothelial NO synthesis (151), NFκB signaling (152), CRP,
or soluble CD40 ligand (sCD40L) (153). Clinical studies on the
use of aspirin for primary prevention of atherosclerosis, however,
have also yielded negative results [recently reviewed by Gaziano
and Greenland (147)]. A large study in a Japanese population
over 60 years of age could demonstrate no benefit of low-dose
aspirin therapy (154, 155). In patients at low risk for cardiovas-
cular events, the use of aspirin needs to be weighed very carefully
against an elevated risk of bleeding events or even hemorrhagic
stroke (147).
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For the ADP-receptor antagonist clopidogrel, reports on an
effect in the context of atherosclerosis exist, too. In animal models,
clopidogrel has the ability to slow down the inflammatory pro-
gression of atherosclerosis (156, 157). Clopidogrel reduces platelet
activation as measured by P-selectin expression and other inflam-
matory markers (158), while others stress that important inflam-
matory markers such as hsCRP are not affected (159, 160). On the
other hand, platelet–leukocyte aggregate formation is inhibited
more effectively by clopidogrel compared to aspirin (161, 162). In
contrast, another group reported that under therapy with clopido-
grel, the expression of some inflammatory chemokines may even
be increased in peripheral blood mononuclear cells in patients
with coronary artery disease (163). On the platelet surface, a
number of inflammatory receptors may represent potential tar-
gets for new therapeutic approaches such as CXCL4, CCL5, CD40
ligand, PSGL-1 (164). Further targets may be platelet-activating
factor (PAF) (165) or Annexin A5 (166). Finally, we have already
described the evidence on complement receptor involvement in
atherosclerosis (126, 167). This class of receptors are involved in
a large number of inflammatory processes (117) and are also
expressed on platelets (120–122). There are a number of sub-
stances targeting different parts of the complement system which
are evaluated in different stages of clinical trials in conditions such
as age-related macular degeneration or hereditary angioedema
(168, 169). Some have even established themselves as first-line
treatment such as eculizumab for paroxysmal nocturnal hemoglo-
binuria (170, 171). It is tempting to speculate, that these substances
might be worth an evaluation in the context of atherosclerosis,
as well.
Moreover, biomarkers of atherosclerosis are of great impor-
tance from a clinical point of view. Due to the high prevalence
of cardiovascular disease, it is vital to identify which patient is
at particular risk for adverse cardiovascular events and would
benefit from preventive diagnostic or therapeutic interventions.
A number of platelet surface receptors may be promising can-
didates to consider in this context. A prominent example is sol-
uble CD40 ligand (sCD40L) released from platelets (172). In a
number of settings such as on hospital admission of patients
with acute coronary syndrome or in patients undergoing pri-
mary angioplasty, sCD40L levels appear to have predictive capacity
(173–175). Some authors even discuss sCD40L as a therapeu-
tic target (176). Apart from sCD40L, soluble P-selectin released
from platelets is referred to as a further potential platelet-derived
biomarker (177, 178).
Considering the achievements of platelet research over the last
two decades with a bounty of platelet-targeted drugs, which found
their way into everyday clinical practice, platelets and platelet-
associated molecular mechanisms offer potential translational
applications.
CONCLUSION
In conclusion, platelets – conceived as immune cells and mediators
of vascular/tissue remodeling – have a strong impact on athero-
sclerosis through inflammatory mechanisms discussed here on the
basis of selected cellular or soluble platelet-derived mediators. The
net effect of platelet-mediated inflammation may be an atheropro-
moting one, although these anucleate cells may mediate distinct
atheroprotective mechanisms, as well. Future investigations will
have to identify these specific platelet aspects to enable us to
develop better diagnostic markers and therapeutic approaches
with fewer undesired side effects.
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